APO Research
Talk to an analyst

APO RESEARCH · REPORT

Long-acting Insulin Glargine

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Long-acting Insulin Glargine Market Outlook and Growth Opportunities 2026

23 December 2025197 pages

Choose your research edition.

Industry ResearchLong-acting Insulin Glargine Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Long-acting Insulin Glargine Industry Growth and Trends Forecast to 2032108 pages · $3,450 USDMarket StructureGlobal Long-acting Insulin Glargine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Long-acting Insulin Glargine Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Long-acting Insulin Glargine Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Long-acting Insulin Glargine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Long-acting Insulin Glargine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Long-acting Insulin Glargine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Long-acting Insulin Glargine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Long-acting Insulin Glargine market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Long-acting Insulin Glargine market include Biocare, Biocon Biologics, Cipla, INFION PHARMA, KALBE PHARMA, Lupin Laboratories, Swixx Biopharma, Viatris and Wockhardt, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Long-acting Insulin Glargine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Long-acting Insulin Glargine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Long-acting Insulin Glargine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Long-acting Insulin Glargine market size, projected growth trends, production technologies, key applications, and end-use industries.

Long-acting Insulin Glargine Segment by Company

Biocare

Biocon Biologics

Cipla

INFION PHARMA

KALBE PHARMA

Lupin Laboratories

Swixx Biopharma

Viatris

Wockhardt

Gan & Lee

Eli Lilly & Co

Sanofi

Tonghua Dongbao

United Laboratories

Long-acting Insulin Glargine Segment by Type

Vial

Prefilled

Long-acting Insulin Glargine Segment by Application

Type 2 Diabetes

Type 1 Diabetes

Long-acting Insulin Glargine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Long-acting Insulin Glargine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Long-acting Insulin Glargine market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Long-acting Insulin Glargine significant trends, drivers, influence factors in global and regions.

6. To analyze Long-acting Insulin Glargine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Long-acting Insulin Glargine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Long-acting Insulin Glargine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Long-acting Insulin Glargine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Long-acting Insulin Glargine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Long-acting Insulin Glargine industry.

Chapter 3: Detailed analysis of Long-acting Insulin Glargine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Long-acting Insulin Glargine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Long-acting Insulin Glargine in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Long-acting Insulin Glargine Industry Trends Table 2. Long-acting Insulin Glargine Industry Drivers Table 3. Long-acting Insulin Glargine Industry Opportunities and Challenges Table 4. Long-acting Insulin Glargine Industry Restraints Table 5. Global Long-acting Insulin Glargine Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Long-acting Insulin Glargine Revenue Share by Company (2021-2026) Table 7. Global Long-acting Insulin Glargine Sales Volume by Company (k units) & (2021-2026) Table 8. Global Long-acting Insulin Glargine Sales Volume Share by Company (2021-2026) Table 9. Global Long-acting Insulin Glargine Average Price (USD/unit) of Company (2021-2026) Table 10. Global Long-acting Insulin Glargine Company Ranking, (2024-2026) & (USD Million) Table 11. Global Long-acting Insulin Glargine Key Company Manufacturing Base & Headquarters Table 12. Global Long-acting Insulin Glargine Company, Product Type & Application Table 13. Global Long-acting Insulin Glargine Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Long-acting Insulin Glargine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Vial Table 18. Significant Companies of Prefilled Table 19. Global Long-acting Insulin Glargine Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 20. Global Long-acting Insulin Glargine Sales Volume by Type (2021-2026) & (k units) Table 21. Global Long-acting Insulin Glargine Sales Volume by Type (2027-2032) & (k units) Table 22. Global Long-acting Insulin Glargine Sales Volume Share by Type (2021-2026) Table 23. Global Long-acting Insulin Glargine Sales Volume Share by Type (2027-2032) Table 24. Global Long-acting Insulin Glargine Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Long-acting Insulin Glargine Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Long-acting Insulin Glargine Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Long-acting Insulin Glargine Sales Value Share by Type (2021-2026) Table 28. Global Long-acting Insulin Glargine Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Type 2 Diabetes Table 30. Significant Companies of Type 1 Diabetes Table 31. Global Long-acting Insulin Glargine Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 32. Global Long-acting Insulin Glargine Sales Volume by Application (2021-2026) & (k units) Table 33. Global Long-acting Insulin Glargine Sales Volume by Application (2027-2032) & (k units) Table 34. Global Long-acting Insulin Glargine Sales Volume Share by Application (2021-2026) Table 35. Global Long-acting Insulin Glargine Sales Volume Share by Application (2027-2032) Table 36. Global Long-acting Insulin Glargine Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Long-acting Insulin Glargine Sales Value by Application (2021-2026) & (US$ Million) Table 38. Global Long-acting Insulin Glargine Sales Value by Application (2027-2032) & (US$ Million) Table 39. Global Long-acting Insulin Glargine Sales Value Share by Application (2021-2026) Table 40. Global Long-acting Insulin Glargine Sales Value Share by Application (2027-2032) Table 41. Global Long-acting Insulin Glargine Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 42. Global Long-acting Insulin Glargine Sales by Region (2021-2026) & (k units) Table 43. Global Long-acting Insulin Glargine Sales Market Share by Region (2021-2026) Table 44. Global Long-acting Insulin Glargine Sales by Region (2027-2032) & (k units) Table 45. Global Long-acting Insulin Glargine Sales Market Share by Region (2027-2032) Table 46. Global Long-acting Insulin Glargine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Long-acting Insulin Glargine Sales Value by Region (2021-2026) & (US$ Million) Table 48. Global Long-acting Insulin Glargine Sales Value Share by Region (2021-2026) Table 49. Global Long-acting Insulin Glargine Sales Value by Region (2027-2032) & (US$ Million) Table 50. Global Long-acting Insulin Glargine Sales Value Share by Region (2027-2032) Table 51. Global Long-acting Insulin Glargine Market Average Price (USD/unit) by Region (2021-2026) Table 52. Global Long-acting Insulin Glargine Market Average Price (USD/unit) by Region (2027-2032) Table 53. Global Long-acting Insulin Glargine Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 54. Global Long-acting Insulin Glargine Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 55. Global Long-acting Insulin Glargine Sales by Country (2021-2026) & (k units) Table 56. Global Long-acting Insulin Glargine Sales Market Share by Country (2021-2026) Table 57. Global Long-acting Insulin Glargine Sales by Country (2027-2032) & (k units) Table 58. Global Long-acting Insulin Glargine Sales Market Share by Country (2027-2032) Table 59. Global Long-acting Insulin Glargine Sales Value by Country (2021-2026) & (US$ Million) Table 60. Global Long-acting Insulin Glargine Sales Value Market Share by Country (2021-2026) Table 61. Global Long-acting Insulin Glargine Sales Value by Country (2027-2032) & (US$ Million) Table 62. Global Long-acting Insulin Glargine Sales Value Market Share by Country (2027-2032) Table 63. Biocare Company Information Table 64. Biocare Business Overview Table 65. Biocare Long-acting Insulin Glargine Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 66. Biocare Long-acting Insulin Glargine Product Portfolio Table 67. Biocare Recent Development Table 68. Biocon Biologics Company Information Table 69. Biocon Biologics Business Overview Table 70. Biocon Biologics Long-acting Insulin Glargine Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 71. Biocon Biologics Long-acting Insulin Glargine Product Portfolio Table 72. Biocon Biologics Recent Development Table 73. Cipla Company Information Table 74. Cipla Business Overview Table 75. Cipla Long-acting Insulin Glargine Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 76. Cipla Long-acting Insulin Glargine Product Portfolio Table 77. Cipla Recent Development Table 78. INFION PHARMA Company Information Table 79. INFION PHARMA Business Overview Table 80. INFION PHARMA Long-acting Insulin Glargine Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 81. INFION PHARMA Long-acting Insulin Glargine Product Portfolio Table 82. INFION PHARMA Recent Development Table 83. KALBE PHARMA Company Information Table 84. KALBE PHARMA Business Overview Table 85. KALBE PHARMA Long-acting Insulin Glargine Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 86. KALBE PHARMA Long-acting Insulin Glargine Product Portfolio Table 87. KALBE PHARMA Recent Development Table 88. Lupin Laboratories Company Information Table 89. Lupin Laboratories Business Overview Table 90. Lupin Laboratories Long-acting Insulin Glargine Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 91. Lupin Laboratories Long-acting Insulin Glargine Product Portfolio Table 92. Lupin Laboratories Recent Development Table 93. Swixx Biopharma Company Information Table 94. Swixx Biopharma Business Overview Table 95. Swixx Biopharma Long-acting Insulin Glargine Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 96. Swixx Biopharma Long-acting Insulin Glargine Product Portfolio Table 97. Swixx Biopharma Recent Development Table 98. Viatris Company Information Table 99. Viatris Business Overview Table 100. Viatris Long-acting Insulin Glargine Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 101. Viatris Long-acting Insulin Glargine Product Portfolio Table 102. Viatris Recent Development Table 103. Wockhardt Company Information Table 104. Wockhardt Business Overview Table 105. Wockhardt Long-acting Insulin Glargine Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 106. Wockhardt Long-acting Insulin Glargine Product Portfolio Table 107. Wockhardt Recent Development Table 108. Gan & Lee Company Information Table 109. Gan & Lee Business Overview Table 110. Gan & Lee Long-acting Insulin Glargine Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 111. Gan & Lee Long-acting Insulin Glargine Product Portfolio Table 112. Gan & Lee Recent Development Table 113. Eli Lilly & Co Company Information Table 114. Eli Lilly & Co Business Overview Table 115. Eli Lilly & Co Long-acting Insulin Glargine Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 116. Eli Lilly & Co Long-acting Insulin Glargine Product Portfolio Table 117. Eli Lilly & Co Recent Development Table 118. Sanofi Company Information Table 119. Sanofi Business Overview Table 120. Sanofi Long-acting Insulin Glargine Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 121. Sanofi Long-acting Insulin Glargine Product Portfolio Table 122. Sanofi Recent Development Table 123. Tonghua Dongbao Company Information Table 124. Tonghua Dongbao Business Overview Table 125. Tonghua Dongbao Long-acting Insulin Glargine Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 126. Tonghua Dongbao Long-acting Insulin Glargine Product Portfolio Table 127. Tonghua Dongbao Recent Development Table 128. United Laboratories Company Information Table 129. United Laboratories Business Overview Table 130. United Laboratories Long-acting Insulin Glargine Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 131. United Laboratories Long-acting Insulin Glargine Product Portfolio Table 132. United Laboratories Recent Development Table 133. Key Raw Materials Table 134. Raw Materials Key Suppliers Table 135. Long-acting Insulin Glargine Distributors List Table 136. Long-acting Insulin Glargine Customers List Table 137. Research Programs/Design for This Report Table 138. Authors List of This Report Table 139. Secondary Sources Table 140. Primary Sources List of Figures Figure 1. Long-acting Insulin Glargine Product Image Figure 2. Global Long-acting Insulin Glargine Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Long-acting Insulin Glargine Sales Value (2021-2032) & (US$ Million) Figure 4. Global Long-acting Insulin Glargine Sales (2021-2032) & (k units) Figure 5. Global Long-acting Insulin Glargine Sales Average Price (USD/unit) & (2021-2032) Figure 6. Global Long-acting Insulin Glargine Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Vial Image Figure 10. Prefilled Image Figure 11. Global Long-acting Insulin Glargine Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 12. Global Long-acting Insulin Glargine Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Long-acting Insulin Glargine Sales Volume Share by Type (2021-2032) Figure 14. Global Long-acting Insulin Glargine Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Long-acting Insulin Glargine Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Long-acting Insulin Glargine Sales Value Share by Type (2021-2032) Figure 17. Type 2 Diabetes Image Figure 18. Type 1 Diabetes Image Figure 19. Global Long-acting Insulin Glargine Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 20. Global Long-acting Insulin Glargine Sales Volume Share 2021 VS 2025 VS 2032 Figure 21. Global Long-acting Insulin Glargine Sales Volume Share by Application (2021-2032) Figure 22. Global Long-acting Insulin Glargine Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Long-acting Insulin Glargine Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global Long-acting Insulin Glargine Sales Value Share by Application (2021-2032) Figure 25. Global Long-acting Insulin Glargine Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 26. Global Long-acting Insulin Glargine Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 27. Global Long-acting Insulin Glargine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 28. Global Long-acting Insulin Glargine Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 29. North America Long-acting Insulin Glargine Sales Value (2021-2032) & (US$ Million) Figure 30. North America Long-acting Insulin Glargine Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Europe Long-acting Insulin Glargine Sales Value (2021-2032) & (US$ Million) Figure 32. Europe Long-acting Insulin Glargine Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Asia-Pacific Long-acting Insulin Glargine Sales Value (2021-2032) & (US$ Million) Figure 34. Asia-Pacific Long-acting Insulin Glargine Sales Value Share by Country (%), 2025 VS 2032 Figure 35. South America Long-acting Insulin Glargine Sales Value (2021-2032) & (US$ Million) Figure 36. South America Long-acting Insulin Glargine Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Middle East & Africa Long-acting Insulin Glargine Sales Value (2021-2032) & (US$ Million) Figure 38. Middle East & Africa Long-acting Insulin Glargine Sales Value Share by Country (%), 2025 VS 2032 Figure 39. USA Long-acting Insulin Glargine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. USA Long-acting Insulin Glargine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. USA Long-acting Insulin Glargine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Canada Long-acting Insulin Glargine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Canada Long-acting Insulin Glargine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Canada Long-acting Insulin Glargine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Mexico Long-acting Insulin Glargine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Mexico Long-acting Insulin Glargine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Mexico Long-acting Insulin Glargine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Germany Long-acting Insulin Glargine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Germany Long-acting Insulin Glargine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Germany Long-acting Insulin Glargine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. France Long-acting Insulin Glargine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. France Long-acting Insulin Glargine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. France Long-acting Insulin Glargine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. U.K. Long-acting Insulin Glargine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. U.K. Long-acting Insulin Glargine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. U.K. Long-acting Insulin Glargine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Italy Long-acting Insulin Glargine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Italy Long-acting Insulin Glargine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Italy Long-acting Insulin Glargine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Spain Long-acting Insulin Glargine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Spain Long-acting Insulin Glargine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Spain Long-acting Insulin Glargine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Russia Long-acting Insulin Glargine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Russia Long-acting Insulin Glargine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Russia Long-acting Insulin Glargine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Netherlands Long-acting Insulin Glargine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Netherlands Long-acting Insulin Glargine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Netherlands Long-acting Insulin Glargine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Nordic Countries Long-acting Insulin Glargine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Nordic Countries Long-acting Insulin Glargine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Nordic Countries Long-acting Insulin Glargine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. China Long-acting Insulin Glargine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. China Long-acting Insulin Glargine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. China Long-acting Insulin Glargine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Japan Long-acting Insulin Glargine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Japan Long-acting Insulin Glargine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Japan Long-acting Insulin Glargine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. South Korea Long-acting Insulin Glargine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. South Korea Long-acting Insulin Glargine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. South Korea Long-acting Insulin Glargine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. India Long-acting Insulin Glargine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. India Long-acting Insulin Glargine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. India Long-acting Insulin Glargine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Australia Long-acting Insulin Glargine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Australia Long-acting Insulin Glargine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Australia Long-acting Insulin Glargine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Southeast Asia Long-acting Insulin Glargine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Southeast Asia Long-acting Insulin Glargine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Southeast Asia Long-acting Insulin Glargine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Brazil Long-acting Insulin Glargine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Brazil Long-acting Insulin Glargine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Brazil Long-acting Insulin Glargine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Argentina Long-acting Insulin Glargine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Argentina Long-acting Insulin Glargine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Argentina Long-acting Insulin Glargine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Chile Long-acting Insulin Glargine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Chile Long-acting Insulin Glargine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Chile Long-acting Insulin Glargine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Colombia Long-acting Insulin Glargine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Colombia Long-acting Insulin Glargine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Colombia Long-acting Insulin Glargine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Peru Long-acting Insulin Glargine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Peru Long-acting Insulin Glargine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Peru Long-acting Insulin Glargine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Saudi Arabia Long-acting Insulin Glargine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Saudi Arabia Long-acting Insulin Glargine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Long-acting Insulin Glargine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Israel Long-acting Insulin Glargine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Israel Arabia Long-acting Insulin Glargine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Israel Arabia Long-acting Insulin Glargine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. UAE Long-acting Insulin Glargine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. UAE Long-acting Insulin Glargine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. UAE Long-acting Insulin Glargine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Turkey Long-acting Insulin Glargine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Turkey Long-acting Insulin Glargine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Turkey Long-acting Insulin Glargine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Iran Long-acting Insulin Glargine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Iran Long-acting Insulin Glargine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Iran Long-acting Insulin Glargine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Egypt Long-acting Insulin Glargine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Egypt Long-acting Insulin Glargine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Egypt Long-acting Insulin Glargine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Long-acting Insulin Glargine Value Chain Figure 124. Manufacturing Cost Structure Figure 125. Long-acting Insulin Glargine Sales Mode & Process Figure 126. Direct Comparison with Distribution Share Figure 127. Distributors Profiles Figure 128. Years Considered Figure 129. Research Process Figure 130. Key Executives Interviewed

Scope & coverage.

Types
  • Vial
  • Prefilled
Applications
  • Type 2 Diabetes
  • Type 1 Diabetes
Companies covered
  • Biocare
  • Biocon Biologics
  • Cipla
  • INFION PHARMA
  • KALBE PHARMA
  • Lupin Laboratories
  • Swixx Biopharma
  • Viatris
  • Wockhardt
  • Gan & Lee
  • Eli Lilly & Co
  • Sanofi
  • Tonghua Dongbao
  • United Laboratories

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Long-acting Insulin Glargine Sales Value (2021-2032)
  4. 1.2.2 Global Long-acting Insulin Glargine Sales Volume (2021-2032)
  5. 1.2.3 Global Long-acting Insulin Glargine Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Long-acting Insulin Glargine Market Dynamics
  1. 2.1 Long-acting Insulin Glargine Industry Trends
  2. 2.2 Long-acting Insulin Glargine Industry Drivers
  3. 2.3 Long-acting Insulin Glargine Industry Opportunities and Challenges
  4. 2.4 Long-acting Insulin Glargine Industry Restraints
3 Long-acting Insulin Glargine Market by Company
  1. 3.1 Global Long-acting Insulin Glargine Company Revenue Ranking in 2025
  2. 3.2 Global Long-acting Insulin Glargine Revenue by Company (2021-2026)
  3. 3.3 Global Long-acting Insulin Glargine Sales Volume by Company (2021-2026)
  4. 3.4 Global Long-acting Insulin Glargine Average Price by Company (2021-2026)
  5. 3.5 Global Long-acting Insulin Glargine Company Ranking (2024-2026)
  6. 3.6 Global Long-acting Insulin Glargine Company Manufacturing Base and Headquarters
  7. 3.7 Global Long-acting Insulin Glargine Company Product Type and Application
  8. 3.8 Global Long-acting Insulin Glargine Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Long-acting Insulin Glargine Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Long-acting Insulin Glargine Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Long-acting Insulin Glargine Market by Type
  1. 4.1 Long-acting Insulin Glargine Type Introduction
  2. 4.1.1 Vial
  3. 4.1.2 Prefilled
  4. 4.2 Global Long-acting Insulin Glargine Sales Volume by Type
  5. 4.2.1 Global Long-acting Insulin Glargine Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Long-acting Insulin Glargine Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Long-acting Insulin Glargine Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Long-acting Insulin Glargine Sales Value by Type
  9. 4.3.1 Global Long-acting Insulin Glargine Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Long-acting Insulin Glargine Sales Value by Type (2021-2032)
  11. 4.3.3 Global Long-acting Insulin Glargine Sales Value Share by Type (2021-2032)
5 Long-acting Insulin Glargine Market by Application
  1. 5.1 Long-acting Insulin Glargine Application Introduction
  2. 5.1.1 Type 2 Diabetes
  3. 5.1.2 Type 1 Diabetes
  4. 5.2 Global Long-acting Insulin Glargine Sales Volume by Application
  5. 5.2.1 Global Long-acting Insulin Glargine Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Long-acting Insulin Glargine Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Long-acting Insulin Glargine Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Long-acting Insulin Glargine Sales Value by Application
  9. 5.3.1 Global Long-acting Insulin Glargine Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Long-acting Insulin Glargine Sales Value by Application (2021-2032)
  11. 5.3.3 Global Long-acting Insulin Glargine Sales Value Share by Application (2021-2032)
6 Long-acting Insulin Glargine Regional Sales and Value Analysis
  1. 6.1 Global Long-acting Insulin Glargine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Long-acting Insulin Glargine Sales by Region (2021-2032)
  3. 6.2.1 Global Long-acting Insulin Glargine Sales by Region: 2021-2026
  4. 6.2.2 Global Long-acting Insulin Glargine Sales by Region (2027-2032)
  5. 6.3 Global Long-acting Insulin Glargine Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Long-acting Insulin Glargine Sales Value by Region (2021-2032)
  7. 6.4.1 Global Long-acting Insulin Glargine Sales Value by Region: 2021-2026
  8. 6.4.2 Global Long-acting Insulin Glargine Sales Value by Region (2027-2032)
  9. 6.5 Global Long-acting Insulin Glargine Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Long-acting Insulin Glargine Sales Value (2021-2032)
  12. 6.6.2 North America Long-acting Insulin Glargine Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Long-acting Insulin Glargine Sales Value (2021-2032)
  15. 6.7.2 Europe Long-acting Insulin Glargine Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Long-acting Insulin Glargine Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Long-acting Insulin Glargine Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Long-acting Insulin Glargine Sales Value (2021-2032)
  21. 6.9.2 South America Long-acting Insulin Glargine Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Long-acting Insulin Glargine Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Long-acting Insulin Glargine Sales Value Share by Country, 2025 VS 2032
7 Long-acting Insulin Glargine Country-level Sales and Value Analysis
  1. 7.1 Global Long-acting Insulin Glargine Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Long-acting Insulin Glargine Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Long-acting Insulin Glargine Sales by Country (2021-2032)
  4. 7.3.1 Global Long-acting Insulin Glargine Sales by Country (2021-2026)
  5. 7.3.2 Global Long-acting Insulin Glargine Sales by Country (2027-2032)
  6. 7.4 Global Long-acting Insulin Glargine Sales Value by Country (2021-2032)
  7. 7.4.1 Global Long-acting Insulin Glargine Sales Value by Country (2021-2026)
  8. 7.4.2 Global Long-acting Insulin Glargine Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Long-acting Insulin Glargine Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Long-acting Insulin Glargine Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Long-acting Insulin Glargine Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Long-acting Insulin Glargine Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Long-acting Insulin Glargine Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Long-acting Insulin Glargine Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Long-acting Insulin Glargine Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Long-acting Insulin Glargine Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Long-acting Insulin Glargine Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Long-acting Insulin Glargine Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Long-acting Insulin Glargine Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Long-acting Insulin Glargine Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Long-acting Insulin Glargine Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Long-acting Insulin Glargine Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Long-acting Insulin Glargine Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Long-acting Insulin Glargine Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Long-acting Insulin Glargine Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Long-acting Insulin Glargine Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Long-acting Insulin Glargine Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Long-acting Insulin Glargine Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Long-acting Insulin Glargine Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Long-acting Insulin Glargine Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Long-acting Insulin Glargine Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Long-acting Insulin Glargine Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Long-acting Insulin Glargine Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Long-acting Insulin Glargine Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Long-acting Insulin Glargine Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Long-acting Insulin Glargine Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Long-acting Insulin Glargine Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Long-acting Insulin Glargine Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Long-acting Insulin Glargine Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Long-acting Insulin Glargine Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Long-acting Insulin Glargine Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Long-acting Insulin Glargine Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Long-acting Insulin Glargine Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Long-acting Insulin Glargine Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Long-acting Insulin Glargine Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Long-acting Insulin Glargine Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Long-acting Insulin Glargine Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Long-acting Insulin Glargine Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Long-acting Insulin Glargine Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Long-acting Insulin Glargine Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Long-acting Insulin Glargine Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Long-acting Insulin Glargine Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Long-acting Insulin Glargine Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Long-acting Insulin Glargine Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Long-acting Insulin Glargine Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Long-acting Insulin Glargine Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Long-acting Insulin Glargine Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Long-acting Insulin Glargine Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Long-acting Insulin Glargine Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Long-acting Insulin Glargine Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Long-acting Insulin Glargine Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Long-acting Insulin Glargine Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Long-acting Insulin Glargine Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Long-acting Insulin Glargine Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Long-acting Insulin Glargine Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Long-acting Insulin Glargine Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Long-acting Insulin Glargine Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Long-acting Insulin Glargine Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Long-acting Insulin Glargine Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Long-acting Insulin Glargine Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Long-acting Insulin Glargine Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Long-acting Insulin Glargine Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Long-acting Insulin Glargine Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Long-acting Insulin Glargine Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Long-acting Insulin Glargine Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Long-acting Insulin Glargine Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Long-acting Insulin Glargine Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Long-acting Insulin Glargine Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Long-acting Insulin Glargine Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Long-acting Insulin Glargine Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Long-acting Insulin Glargine Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Long-acting Insulin Glargine Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Long-acting Insulin Glargine Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Long-acting Insulin Glargine Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Long-acting Insulin Glargine Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Long-acting Insulin Glargine Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Long-acting Insulin Glargine Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Long-acting Insulin Glargine Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Long-acting Insulin Glargine Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Long-acting Insulin Glargine Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Long-acting Insulin Glargine Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Long-acting Insulin Glargine Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Biocare
  2. 8.1.1 Biocare Company Information
  3. 8.1.2 Biocare Business Overview
  4. 8.1.3 Biocare Long-acting Insulin Glargine Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Biocare Long-acting Insulin Glargine Product Portfolio
  6. 8.1.5 Biocare Recent Developments
  7. 8.2 Biocon Biologics
  8. 8.2.1 Biocon Biologics Company Information
  9. 8.2.2 Biocon Biologics Business Overview
  10. 8.2.3 Biocon Biologics Long-acting Insulin Glargine Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Biocon Biologics Long-acting Insulin Glargine Product Portfolio
  12. 8.2.5 Biocon Biologics Recent Developments
  13. 8.3 Cipla
  14. 8.3.1 Cipla Company Information
  15. 8.3.2 Cipla Business Overview
  16. 8.3.3 Cipla Long-acting Insulin Glargine Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Cipla Long-acting Insulin Glargine Product Portfolio
  18. 8.3.5 Cipla Recent Developments
  19. 8.4 INFION PHARMA
  20. 8.4.1 INFION PHARMA Company Information
  21. 8.4.2 INFION PHARMA Business Overview
  22. 8.4.3 INFION PHARMA Long-acting Insulin Glargine Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 INFION PHARMA Long-acting Insulin Glargine Product Portfolio
  24. 8.4.5 INFION PHARMA Recent Developments
  25. 8.5 KALBE PHARMA
  26. 8.5.1 KALBE PHARMA Company Information
  27. 8.5.2 KALBE PHARMA Business Overview
  28. 8.5.3 KALBE PHARMA Long-acting Insulin Glargine Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 KALBE PHARMA Long-acting Insulin Glargine Product Portfolio
  30. 8.5.5 KALBE PHARMA Recent Developments
  31. 8.6 Lupin Laboratories
  32. 8.6.1 Lupin Laboratories Company Information
  33. 8.6.2 Lupin Laboratories Business Overview
  34. 8.6.3 Lupin Laboratories Long-acting Insulin Glargine Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Lupin Laboratories Long-acting Insulin Glargine Product Portfolio
  36. 8.6.5 Lupin Laboratories Recent Developments
  37. 8.7 Swixx Biopharma
  38. 8.7.1 Swixx Biopharma Company Information
  39. 8.7.2 Swixx Biopharma Business Overview
  40. 8.7.3 Swixx Biopharma Long-acting Insulin Glargine Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Swixx Biopharma Long-acting Insulin Glargine Product Portfolio
  42. 8.7.5 Swixx Biopharma Recent Developments
  43. 8.8 Viatris
  44. 8.8.1 Viatris Company Information
  45. 8.8.2 Viatris Business Overview
  46. 8.8.3 Viatris Long-acting Insulin Glargine Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Viatris Long-acting Insulin Glargine Product Portfolio
  48. 8.8.5 Viatris Recent Developments
  49. 8.9 Wockhardt
  50. 8.9.1 Wockhardt Company Information
  51. 8.9.2 Wockhardt Business Overview
  52. 8.9.3 Wockhardt Long-acting Insulin Glargine Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Wockhardt Long-acting Insulin Glargine Product Portfolio
  54. 8.9.5 Wockhardt Recent Developments
  55. 8.10 Gan & Lee
  56. 8.10.1 Gan & Lee Company Information
  57. 8.10.2 Gan & Lee Business Overview
  58. 8.10.3 Gan & Lee Long-acting Insulin Glargine Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Gan & Lee Long-acting Insulin Glargine Product Portfolio
  60. 8.10.5 Gan & Lee Recent Developments
  61. 8.11 Eli Lilly & Co
  62. 8.11.1 Eli Lilly & Co Company Information
  63. 8.11.2 Eli Lilly & Co Business Overview
  64. 8.11.3 Eli Lilly & Co Long-acting Insulin Glargine Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Eli Lilly & Co Long-acting Insulin Glargine Product Portfolio
  66. 8.11.5 Eli Lilly & Co Recent Developments
  67. 8.12 Sanofi
  68. 8.12.1 Sanofi Company Information
  69. 8.12.2 Sanofi Business Overview
  70. 8.12.3 Sanofi Long-acting Insulin Glargine Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Sanofi Long-acting Insulin Glargine Product Portfolio
  72. 8.12.5 Sanofi Recent Developments
  73. 8.13 Tonghua Dongbao
  74. 8.13.1 Tonghua Dongbao Company Information
  75. 8.13.2 Tonghua Dongbao Business Overview
  76. 8.13.3 Tonghua Dongbao Long-acting Insulin Glargine Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Tonghua Dongbao Long-acting Insulin Glargine Product Portfolio
  78. 8.13.5 Tonghua Dongbao Recent Developments
  79. 8.14 United Laboratories
  80. 8.14.1 United Laboratories Company Information
  81. 8.14.2 United Laboratories Business Overview
  82. 8.14.3 United Laboratories Long-acting Insulin Glargine Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 United Laboratories Long-acting Insulin Glargine Product Portfolio
  84. 8.14.5 United Laboratories Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Long-acting Insulin Glargine Value Chain Analysis
  2. 9.1.1 Long-acting Insulin Glargine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Long-acting Insulin Glargine Sales Mode & Process
  6. 9.2 Long-acting Insulin Glargine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Long-acting Insulin Glargine Distributors
  9. 9.2.3 Long-acting Insulin Glargine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst